Thermo Fisher Scientific reported fourth‑quarter 2025 results that surpassed consensus estimates, with revenue rising to $12.21 billion—up 7% year‑over‑year—and adjusted earnings per share of $6.57, a $0.13 beat over the $6.44 consensus. The company’s adjusted operating margin held at 23.6%, slightly below the 23.9% margin recorded in Q4 2024, reflecting modest compression from tariff and foreign‑exchange headwinds.
Revenue growth was driven by robust demand in the Life Sciences Solutions and Analytical Instruments segments, which together grew 4% and 5% respectively. Organic revenue increased 3%, indicating that the company’s pricing power and product mix were largely unchanged, while the modest decline in the Specialty Diagnostics segment was offset by gains in the Laboratory Products and Biopharma Services line. The 7% revenue beat was largely attributable to a 2% increase in customer spend on high‑margin biopharma services and a 1% lift in analytical instrument sales.
The adjusted operating margin contraction of 30 basis points year‑over‑year was caused by higher input costs and tariff‑related expenses that partially eroded the margin advantage enjoyed in the previous year. Management noted that the company’s cost‑control initiatives—such as supply‑chain optimization and workforce efficiency programs—helped limit the impact, but the margin compression signals that pricing power is being challenged by external cost pressures.
For 2026, Thermo Fisher guided total revenue of $46.3 billion to $47.2 billion, implying 4%–6% growth, and adjusted EPS of $24.22 to $24.80, a 6%–8% increase from the prior year. The company also set a 50‑basis‑point margin expansion target, acknowledging that the 2026 EPS guidance falls short of the midpoint of analyst expectations, which contributed to a muted market reaction. The guidance reflects confidence in continued demand from pharmaceutical and biotech customers, while recognizing the need to balance margin expansion against the dilution expected from the pending Clario acquisition and ongoing investments in AI integration.
Investors reacted cautiously, focusing on the slight margin compression and the conservative EPS outlook for 2026. The muted response underscores the importance of profitability metrics to market participants, even as the company delivered a solid earnings beat. Management emphasized that the company’s “PPI Business System” and strategic focus on biopharma reshoring are expected to sustain operational excellence and support the guidance trajectory.
Marc N. Casper, Chairman, President and CEO, said the quarter “demonstrated outstanding execution and the continued strength of our proven growth strategy.” He added that the company’s “active year for capital deployment, including significant M&A activity and returns to shareholders,” positions Thermo Fisher to deliver on its 2026 objectives and build an even brighter future for the company.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.